Skip to main content
Clinical Trials/ITMCTR1900025326
ITMCTR1900025326
Recruiting
Phase 2

Exploring the effectiveness characteristics and preliminary observation of its safety of Huanglian Jiedu Pills in the treatment of excess heat fire-toxicity syndrome: a randomized, double-blind, placebo-controlled, multi-center phase II clinical trial

The Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine0 sitesTBD

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Not specified
Sponsor
The Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine
Status
Recruiting
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional study
Sex
All

Investigators

Sponsor
The Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine

Eligibility Criteria

Inclusion Criteria

  • (1\) Aged 18\-65 years, male or female;
  • (2\) In line with the syndrome differentiation standard of excess heat fire\-toxicity,use the diagnostic Rating Scale of the type of syndrome in the previous period to determine;
  • (3\) In line with one of the diagnostic criteria for oral ulcers, gingivitis or acute pharyngitis;
  • (4\) Within 2 days before enrollment no medication was used;
  • (5\) The patient has understood the test content and has signed the informed consent form,the process of obtaining informed consent is in compliance with GCP regulations.

Exclusion Criteria

  • (1\) Body temperature \> 38\.0 degree C or blood WBC \> 11\.0x10^9 /L or NEUT% \> 85%;
  • (2\) With severe heart disease(Unstable angina ,Acute myocardial infarction within 6 months, severe arrhythmia, grade IV cardiac function, etc.) Severe respiratory disease (Acute bronchial asthma, chronic obstructive pulmonary disease, etc.) or other serious diseases.
  • (3\) Combined with severe liver and kidney damage (AST or ALT \> 1\.5 upper limits of normal,or TBil\> upper limit of normal value,Or Cr\> upper limit of the normal range);
  • (4\) This is not suitable which Body deficient cold of spleen and stomach for taking this product;
  • (5\) Women within 5 days (including 5 days) before menstruation;
  • (6\) Dysphagia or gastrointestinal system surgery affects drug absorption;
  • (7\) Positive pregnancy test, pregnant or lactating women, planned pregnancy;
  • (8\) Disabled patients prescribed by law (blindness, deafness, dumbness, mental retardation, mental disorders, etc.);
  • (9\) Can not follow the interventions specified in the program, plan to accept other disease treatment measures during the trial period;
  • (10\) Failure to follow the program rules for recording journal cards and regular followers;

Outcomes

Primary Outcomes

Not specified

Similar Trials